Live Analyst Rating Changes 26825 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yuan Zhi
BR

Yuan Zhi

B. Riley Securities
Wall Street Analyst
★★☆☆☆
#2282
on 13Foresight · ranked by our own returns
43%
Success Rate
+1.8%
Average Return
10 of 23 calls profitable · +22.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Yuan Zhi's ratings turned a profit when each position was held for 1 year — averaging +1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 1 Hold 0 Sell
Yuan's Stock Coverage 17 ratings · 2026-08-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
LNTH
Lantheus
 Aug 18, 2026 HOLD Buy
-19.1% avg upside
21 analysts
$105.40
5.38% Upside
 · ·
HYPR
Hyperfine
 Aug 10, 2026 BUY Strong Buy
+124.5% avg upside
7 analysts
$1.60
77.41% Upside
 -5.1% ·
STLN
Starling Oncology Institute
 Aug 07, 2026 BUY Strong Buy
+8.9% avg upside
7 analysts
$11.00
70.14% Upside
 +3.9% ·
MIR
Mirion Technologies
 Jul 30, 2026 BUY Strong Buy
+62.3% avg upside
10 analysts
$29.00
95.69% Upside
 -0.1% ·
LYEL
Lyell Immunopharma
 Jul 22, 2026 BUY Strong Buy
+78.5% avg upside
12 analysts
$44.00
183.30% Upside
 +22.7% ·
WHWK
Whitehawk Therapeutics
 Jun 25, 2026 BUY Buy
+163.5% avg upside
14 analysts
$10.00
111.32% Upside
 +15.8% ·
TNGX
Tango Therapeutics
 Jun 09, 2026 BUY Strong Buy
+64.6% avg upside
15 analysts
$35.00
46.47% Upside
 -19.4% ·
RDNT
Radnet
 May 01, 2026 BUY Strong Buy
+6.3% avg upside
11 analysts
$83.00
8.05% Upside
 +35.3% ·
SRTA
Strata Critical Medical
 Mar 25, 2026 BUY Strong Buy
+16.0% avg upside
11 analysts
$8.00
28.17% Upside
 +34.7% ·
CATX
Perspective Therapeutics
 Mar 18, 2026 BUY Strong Buy
+233.8% avg upside
22 analysts
$13.00
293.96% Upside
 -32.1% ·
FHTX
Foghorn Therapeutics
 Dec 17, 2025 BUY Strong Buy
+68.8% avg upside
17 analysts
$10.00
41.49% Upside
 +51.1% ·
RADX
Radiopharm Theranostics Limited Sponsored ADR
 Dec 16, 2025 BUY Strong Buy
+656.1% avg upside
6 analysts
$16.00
555.78% Upside
 -57.3% ·
CTSO
Cytosorbents
 Oct 02, 2024 BUY Strong Buy
+3173.0% avg upside
13 analysts
$3.00
710.89% Upside
 -26.5% ·
ATNM
Actinium Pharmaceuticals
 Aug 07, 2024 HOLD Strong Buy
+524.6% avg upside
11 analysts
$2.00
81.88% Upside
 -25.7% ·
CYRX
CryoPort
 Jul 30, 2024 BUY Strong Buy
-4.3% avg upside
15 analysts
$15.00
12.52% Downside
 -16.7% ·
AZTA
Azenta
 Feb 07, 2024 BUY Buy
+30.6% avg upside
13 analysts
$79.00
111.20% Upside
 -19.6% ·
BLFS
BioLife Solutions
 Jan 09, 2023 BUY Buy
-20.4% avg upside
17 analysts
$34.00
8.35% Downside
 -14.8% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yuan Zhi — Frequently Asked Questions
How accurate are Yuan Zhi's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Yuan's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, or +22.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yuan ranked on 13Foresight?
Yuan Zhi is currently ranked #2282 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yuan cover?
Yuan most recently has ratings on LNTH, HYPR, STLN, MIR, LYEL, WHWK, TNGX, RDNT, SRTA, CATX, FHTX, RADX and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.